Skip to content
Clinical Trials – home
HungaryBack to Hungary

Clinical trials in Farkasgyepu – page 9

162 clinical trials in Farkasgyepu, Hungary. Every trial is listed in the EU Clinical Trials Register and updated daily.

Farkasgyepu at a glance
162
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

162 trials in Farkasgyepu

Open in trial search

Study of GLPG3667 for Adults with Active Systemic Lupus Erythematosus

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:GLPG3667 fumarate
  • Sponsor:Lakefront Biotherapeutics

Psoriatic arthropathy

Not recruiting

Study on Deucravacitinib and Apremilast for Patients with Active Psoriatic Arthritis New to Biologic Treatments or Previously on TNFα Inhibitors

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Apremilast
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Psoriasis

Not recruiting

Study on the Effectiveness and Safety of JNJ-77242113 for Treating Moderate to Severe Plaque Psoriasis in Adults

Investigational
Countries:HungaryHungary
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Icotrokinra
  • Sponsor:Janssen - Cilag International

Rheumatoid arthritis

Not recruiting

Study Comparing Upadacitinib, Placebo, and Adalimumab for Patients with Moderate to Severe Rheumatoid Arthritis on Stable Methotrexate Treatment

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Psoriatic arthropathy

Not recruiting

Study on Izokibep for Improving Symptoms in Patients with Active Psoriatic Arthritis

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Izokibep
  • Sponsor:Acelyrin Inc.

Study on the Effectiveness and Safety of Deucravacitinib for Patients with Active Systemic Lupus Erythematosus (SLE)

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Deucravacitinib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Hypertriglyceridaemia

Not recruiting

Study of ISIS 678354 for Patients with Severe Hypertriglyceridemia

InvestigationalNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:ISIS 678354 sodium salt
  • Sponsor:Ionis Pharmaceuticals Inc.

Atrial fibrillation

Not recruiting

Study on the Effectiveness of Abelacimab for High-Risk Atrial Fibrillation Patients Unsuitable for Oral Anticoagulation

Investigational
Countries:HungaryHungary
  • Participants:65+ years
  • Substances:Abelacimab
  • Sponsor:Anthos Therapeutics Inc.

Colitis ulcerative

Not recruiting

Study on the Effectiveness and Safety of PB016 and Vedolizumab for Patients with Moderately to Severely Active Ulcerative Colitis

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Vedolizumab
  • Sponsor:Polpharma Biologics S.A.

Atrial fibrillation

Not recruiting

Study on Milvexian and Apixaban for Preventing Stroke in Patients with Atrial Fibrillation

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Andexanet Alfa
  • Sponsor:Janssen - Cilag International

Arteriosclerosis

Not recruiting

Study on Inclisiran for Preventing Heart Disease in High-Risk Patients

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Inclisiran
  • Sponsor:Novartis Pharma AG

Psoriasis

Not recruiting

Study on the Effectiveness and Safety of DC-806 for Adults with Moderate to Severe Plaque Psoriasis

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:DC-806
  • Sponsor:DICE Therapeutics Inc.

Other cities in Hungary

The busiest research cities in the country

All 73 cities in Hungary

Clinical research in Farkasgyepu

What the registry says about research in the country

01 Lung Cancer Immunotherapy

Innovative clinical trials exploring immunotherapy combinations for advanced non-small cell lung cancer (NSCLC), focusing on treatment options for patients with various stages of the disease.

  • Novel immunotherapy combinations
  • PD-L1 targeted therapies
  • First-line treatment strategies

Research aims to improve survival rates and treatment outcomes through targeted immunological approaches.

02 Advanced NSCLC Treatments

Studies evaluating targeted therapies for specific mutations in non-small cell lung cancer, including HER2 and KRAS G12C mutations.

  • Mutation-specific treatments
  • Combination therapy approaches
  • Novel drug development

Investigations focus on personalized treatment strategies for different NSCLC subtypes.

03 Small Cell Lung Cancer Research

Clinical trials examining new therapeutic options for small cell lung cancer, including novel drug combinations and comparative effectiveness studies.

  • Single-agent therapies
  • Combination treatments
  • Survival outcome studies

Research focuses on improving treatment options for patients with relapsed SCLC.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.